Identification and Separation of Normal Hematopoietic Stem Cells and Leukemia Stem Cells from Patients with Acute Myeloid Leukemia

  • Van T. Hoang
  • Isabel Hoffmann
  • Karina Borowski
  • Abraham Zepeda-Moreno
  • Dan Ran
  • Eike C. Buss
  • Patrick Wuchter
  • Volker Eckstein
  • Anthony D. Ho
Part of the Methods in Molecular Biology book series (MIMB, volume 1035)


Mounting evidences indicate that leukemic cells in patients with acute myeloid leukemia (AML) are derived from leukemia stem cells (LSC). In analogy to normal hematopoietic stem cells (HSC), LSC remain mostly dormant and are hence resistant to conventional chemotherapy. Residual, physiological HSC exist alongside with LSC, with heterogeneous dominance of LSC over HSC in individual patients. We have devised a flow cytometric method for the identification and separation of these two stem cell populations based on surface antigen markers such as CD34, CD38, lineage aberrant markers, and aldehyde dehydrogenase (ALDH) enzyme activity.

Key words

Acute myeloid leukemia Leukemia stem cells Hematopoietic stem cells Flow cytometry FACS Aldehyde dehydrogenase Aberrant markers 



Aldehyde dehydrogenase


Aberrant marker


Acute myeloid leukemia




Forward scatter


Fluorescence-activated cell sorting




Hematopoietic stem cell


Leukemia stem cells


Mononuclear cells


Non-Obese Diabetic/Severe Combined Immune Deficiency


NOD/SCID/interleukin 2 receptor gammanull




Propidium iodide


Side scatter


  1. 1.
    Lowenberg B, Downing JR, Burnett A (1999) Medical progress—acute myeloid leukemia. N Engl J Med 341(14):1051–1062PubMedCrossRefGoogle Scholar
  2. 2.
    Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368(9550):1894–1907. doi: S0140-6736(06)69780-8 [pii]. 10.1016/S0140-6736(06)69780-8 PubMedCrossRefGoogle Scholar
  3. 3.
    Hoang VT, Zepeda-Moreno A, Ho AD (2012) Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance. Biotechnol J 7(6):779–788. doi: 10.1002/biot.201100350 PubMedCrossRefGoogle Scholar
  4. 4.
    Buss EC, Ho AD (2011) Leukemia stem cells. Int J Cancer 129(10):2328–2336. doi: 10.1002/ijc.26318 PubMedCrossRefGoogle Scholar
  5. 5.
    Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, Fukata M, Miyamoto T, Lyons B, Ohshima K, Uchida N, Taniguchi S, Ohara O, Akashi K, Harada M, Shultz LD (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25(11):1315–1321. doi: nbt1350 [pii]. 10.1038/nbt1350 PubMedCrossRefGoogle Scholar
  6. 6.
    Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730–737PubMedCrossRefGoogle Scholar
  7. 7.
    Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645–648. doi: 10.1038/367645a0 PubMedCrossRefGoogle Scholar
  8. 8.
    Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J, Canty AJ, Danska JS, Bohlander SK, Buske C, Minden MD, Golub TR, Jurisica I, Ebert BL, Dick JE (2011) Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17(9):1086–1093. doi: 10.1038/nm.2415nm.2415 [pii] PubMedCrossRefGoogle Scholar
  9. 9.
    Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, Swider CR, Strzelecki AC, Cavelier C, Recher C, Mansat-De Mas V, Delabesse E, Danet-Desnoyers G, Carroll M (2011) Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest 121(1):384–395. doi: 10.1172/JCI4149541495 [pii] PubMedCrossRefGoogle Scholar
  10. 10.
    Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, Lister TA, Gribben JG, Bonnet D (2010) Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 115(10):1976–1984. doi: blood-2009-02-206565 [pii]. 10.1182/blood-2009-02-206565 PubMedCrossRefGoogle Scholar
  11. 11.
    Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ (1997) Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 89(9):3104–3112PubMedGoogle Scholar
  12. 12.
    Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14(10):1777–1784PubMedCrossRefGoogle Scholar
  13. 13.
    van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ (2007) Aberrant marker expression patterns on the CD34 + CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 21(8):1700–1707. doi: 2404754 [pii]. 10.1038/sj.leu.2404754 PubMedCrossRefGoogle Scholar
  14. 14.
    Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, Krensky AM, Weissman IL (2007) CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 104(26):11008–11013. doi: 0704271104 [pii]. 10.1073/pnas.0704271104 PubMedCrossRefGoogle Scholar
  15. 15.
    Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138(2):286–299. doi: S0092-8674(09)00650-3 [pii]. 10.1016/j.cell.2009.05.045 PubMedCrossRefGoogle Scholar
  16. 16.
    Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R (2011) Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA 108(12):5009–5014. doi: 1100551108 [pii]. 10.1073/pnas.1100551108 PubMedCrossRefGoogle Scholar
  17. 17.
    Ma I, Allan AL (2011) The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7(2):292–306. doi: 10.1007/s12015-010-9208-4 PubMedCrossRefGoogle Scholar
  18. 18.
    Hess DA, Meyerrose TE, Wirthlin L, Craft TP, Herrbrich PE, Creer MH, Nolta JA (2004) Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 104(6):1648–1655. doi: 10.1182/blood-2004-02-0448 2004-02-0448 [pii] PubMedCrossRefGoogle Scholar
  19. 19.
    Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, Lister TA, Bonnet D (2005) Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 23(6):752–760. doi: 23/6/752 [pii]. 10.1634/stemcells.2004-0292 PubMedCrossRefGoogle Scholar
  20. 20.
    Corti S, Locatelli F, Papadimitriou D, Donadoni C, Salani S, Del Bo R, Strazzer S, Bresolin N, Comi GP (2006) Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells 24(4):975–985. doi: 2005-0217 [pii]. 10.1634/stemcells.2005-0217 PubMedCrossRefGoogle Scholar
  21. 21.
    Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567. doi: S1934-5909(07)00133-6 [pii]. 10.1016/j.stem.2007.08.014 PubMedCrossRefGoogle Scholar
  22. 22.
    Ran D, Schubert M, Pietsch L, Taubert I, Wuchter P, Eckstein V, Bruckner T, Zoeller M, Ho AD (2009) Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol 37(12):1423–1434. doi: S0301-472X(09)00390-7 [pii]. 10.1016/j.exphem.2009.10.001 PubMedCrossRefGoogle Scholar
  23. 23.
    Schubert M, Herbert N, Taubert I, Ran D, Singh R, Eckstein V, Vitacolonna M, Ho AD, Zoller M (2011) Differential survival of AML subpopulations in NOD/SCID mice. Exp Hematol 39(2):250–263.e4. doi: S0301-472X(10)00548-5 [pii]. 10.1016/j.exphem.2010.10.010 PubMedCrossRefGoogle Scholar
  24. 24.
    Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69(8):3382–3389. doi: 0008-5472.CAN-08-4418 [pii]. 10.1158/0008-5472.CAN-08-4418 PubMedCrossRefGoogle Scholar
  25. 25.
    Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, Stass SA, Jiang F (2010) ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome. Lab Invest 90(2):234–244. doi: labinvest2009127 [pii]. 10.1038/labinvest.2009.127 PubMedCrossRefGoogle Scholar
  26. 26.
    Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, Galkin S, Collector MI, Perkins B, Levis MJ, Griffin CA, Sharkis SJ, Borowitz MJ, Karp JE, Jones RJ (2012) A clinically relevant population of leukemic CD34 + CD38- cells in acute myeloid leukemia. Blood 119(15):3571–3577. doi: blood-2011-06-364182 [pii]. 10.1182/blood-2011-06-364182 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Van T. Hoang
    • 1
  • Isabel Hoffmann
    • 1
  • Karina Borowski
    • 1
  • Abraham Zepeda-Moreno
    • 1
  • Dan Ran
    • 1
  • Eike C. Buss
    • 1
  • Patrick Wuchter
    • 1
  • Volker Eckstein
    • 1
  • Anthony D. Ho
    • 1
  1. 1.Department of Internal Medicine VUniversity of HeidelbergHeidelbergGermany

Personalised recommendations